Generate Biomedicines, Inc.
A Massachusetts biotech company that uses machine learning to design entirely new protein-based medicines from scratch, rather than hunting for molecules that already exist in nature. Founded in 2018 inside Flagship Pioneering's incubator, it spent its first three years in stealth before publicly launching its platform in 2020. The name reflects the mission: where other firms "discover" drugs, this one *generates* them.
Bought 4.69M
Bought 4.69M
Bought 20.0K
Bought 1.5K
Bought 2.0K
Bought 300
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Afeyan Noubar +7 co-filersDirector, 10% owner, 10% owner · 8 transactions | — | 62.67M | — | 4.69M | — |
| Afeyan Noubar +6 co-filersDirector, 10% owner, 10% owner · 8 transactions | — | 59.55M | — | 4.69M | — |
| Nally MichaelChief Executive Officer, Director · 2 transactions | — | 4.99M | — | 20.0K | — |
| Bancel StephaneDirector · 1 transaction | — | 1.18M | — | — | — |
| Mendillo Jane LDirector · 1 transaction | — | 1.5K | — | 1.5K | — |
| Silvers JasonPresident & CFO · 3 transactions | — | 1.5K | — | 2.0K | — |
| Grous BethChief People Officer · 1 transaction | — | 300 | — | 300 | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +9.40M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.